Rigel Pharmaceuticals
RIGL
122 hedge funds and large institutions have $197M invested in Rigel Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 41 increasing their positions, 44 reducing their positions, and 10 closing their positions.
50% more call options, than puts
Call options by funds: $57K | Put options by funds: $38K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 123 → 122 (-1)
7% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 44
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
22% less capital invested
Capital invested by funds: $253M → $197M (-$56M)
Top Buyers
Top Sellers
| 1 |
BC
Broadfin Capital
New York
|
-$2.24M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$1.14M |
| 3 |
Two Sigma Investments
New York
|
-$886K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$650K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$624K |
RIGL Hedge Fund Activity: Q3 2015 in Review
122 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2015, worth a combined $197M — down 22% from $253M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RIGL and 9 opened new positions — a net loss of 1 holder — while 44 trimmed existing stakes and 41 added.
The largest buyer was Wellington Management Group, adding an estimated $2.6M. The largest seller was Broadfin Capital, cutting an estimated $2.24M.
- 122 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2015, down from 123 in Q2 2015.
- Funds reported $197M of Rigel Pharmaceuticals stock for Q3 2015, down 22% quarter-over-quarter.
- 9 funds opened new Rigel Pharmaceuticals positions in Q3 2015 and 10 closed out, a net change of -1 holder.
- The largest Rigel Pharmaceuticals buyer in Q3 2015 was Wellington Management Group, an estimated $2.6M added.
- The largest Rigel Pharmaceuticals seller in Q3 2015 was Broadfin Capital, an estimated $2.24M sold.
Based on aggregated 13F filings for Q3 2015.